GLP-1 Drugs Are Doing Far More Than Anyone Expected

They were approved for diabetes. Then weight loss. Now the evidence is pointing somewhere far more surprising — addiction, Alzheimer's, concussion, kidney disease, and beyond. Here's what the 2025 and 2026 research actually shows.

When GLP-1 receptor agonists first entered mainstream consciousness as weight loss medications, the story seemed simple enough. Suppress appetite, reduce food intake, lose weight. The mechanism was elegantly straightforward.

What has emerged since is considerably more complex — and considerably more interesting. GLP-1 receptors are not confined to the gut and pancreas. They are present throughout the body, including in the brain, heart, kidneys, and immune system. As more people have taken these medications for longer periods, and as researchers have looked harder, the picture of what GLP-1 drugs actually do has expanded in ways that were not anticipated.

A January 2026 review in Nature Medicine — one of the highest-impact medical journals in existence — described GLP-1 medicines as reshaping modern health care through effects far beyond glycaemic control and weight loss. A May 2025 systematic review found pleiotropic effects through fundamental cellular mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control across multiple organ systems.

This article covers what the evidence actually shows across the emerging indications — and where the line sits between established benefit and promising but preliminary findings.

TL;DR

• GLP-1 drugs demonstrate a 14 to 20% reduction in major adverse cardiovascular events — now FDA and MHRA approved for cardiovascular risk reduction in people with obesity and established cardiovascular disease.
• Semaglutide was FDA-approved in January 2025 for chronic kidney disease in patients with type 2 diabetes, following a trial stopped early due to its strong findings.
• Tirzepatide was approved for obstructive sleep apnoea in obese adults in 2024, producing meaningful improvements in AHI independent of weight loss.
• 33 clinical trials of GLP-1 drugs for substance use disorders are currently registered, primarily focused on alcohol and nicotine, following consistent preclinical and early clinical signals.
• Semaglutide failed two major Alzheimer's trials but researchers remain cautiously optimistic — the concussion and TBI angle is earlier stage but mechanistically compelling.

A 2025 University of Florida study found GLP-1 medications associated with a 17% lower risk of developing 14 obesity-associated cancers.

Mood flattening and apathy are emerging as real side effects warranting investigation alongside the expanding benefits.

How GLP-1 Drugs Work Beyond the Gut

Understanding the expanding benefit profile of GLP-1 drugs requires understanding where GLP-1 receptors actually exist in the body.

GLP-1 receptors are present throughout the central and peripheral nervous system — in the brainstem, hypothalamus, limbic system, and cortex — as well as in the heart, kidneys, immune cells, and lungs. When GLP-1 receptor agonist medications activate these receptors, they produce effects far beyond the gastric emptying and satiety signalling that explain weight loss.

The fundamental cellular mechanisms identified in the 2025 systematic review include enhanced mitochondrial function — improving cellular energy production across multiple tissue types — anti-inflammatory actions that reduce chronic low-grade inflammation, improved autophagy (cellular quality control), and direct receptor-mediated effects in target tissues independent of metabolic changes.

This last point is critical for understanding the emerging indications: many of the non-metabolic benefits of GLP-1 drugs appear to be independent of weight loss or glycaemic control. People who lose significant weight through other means do not necessarily show the same cardiovascular, renal, or neurological benefits — suggesting the drugs are doing something beyond the downstream effects of metabolic improvement.

Cardiovascular Disease: The Most Established Non-Metabolic Benefit

The cardiovascular story is now well established and represents the most clearly evidenced expansion of GLP-1 indications beyond diabetes and weight loss.

The landmark SELECT trial demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in overweight or obese adults with established cardiovascular disease but without diabetes. This led to FDA approval in March 2024 for cardiovascular risk reduction in this population.

The May 2025 systematic review confirmed a 14 to 20% reduction in major adverse cardiovascular events across GLP-1 trials — a consistent and clinically meaningful effect. The January 2026 Nature Medicine review described this as one of the most robustly established applications of GLP-1 medicines outside metabolic disease.

The cardiovascular mechanism operates through multiple pathways: direct activation of cardiac GLP-1 receptors that improve heart muscle function, reduction of systemic inflammation that drives atherosclerosis, improved endothelial function, reduced blood pressure, and beneficial changes in lipid profiles — all partially independent of the metabolic benefits.

A separate clinical trial found that tirzepatide meaningfully reduced the risk of serious heart-related problems and improved overall health in obese patients with heart failure with preserved ejection fraction — a form of heart failure for which effective treatments have historically been limited.

Kidney Disease: FDA Approved in January 2025

The renal benefits of GLP-1 medications represent another area where the evidence is now sufficient for regulatory approval.

In a clinical trial with over 3,500 patients, semaglutide significantly reduced the risk of kidney complications in patients with both type 2 diabetes and chronic kidney disease — with improvements in disease severity that were unrelated to changes in body weight. The trial was stopped early due to the strength of its findings. In January 2025, the FDA approved Ozempic to treat chronic kidney disease in patients with type 2 diabetes.

The kidney protection mechanism is likely multifactorial — combining reduced glomerular hyperfiltration, reduced systemic inflammation, and direct GLP-1 receptor effects in renal tissue. The weight-independence of some of these effects suggests direct organ-level protection rather than purely metabolic benefit.

Sleep Apnoea: An Approved Indication

Obstructive sleep apnoea is one of the more recent and practically relevant approved indications for GLP-1 medications.

Tirzepatide was approved in 2024 for managing moderate-to-severe obstructive sleep apnoea in obese adults. The mechanism involves both the direct effect of weight loss on upper airway anatomy and — in some research — direct effects on the upper airway musculature and central respiratory regulation through GLP-1 receptors in the brainstem. Some improvement in OSA metrics has been observed in patients beyond what weight loss alone would predict, suggesting a direct respiratory mechanism is also at work.

For the many people whose sleep apnoea is closely linked to excess weight, GLP-1 medications represent one of the most effective non-surgical interventions available — addressing the metabolic root cause rather than managing the respiratory symptoms with CPAP alone.

Liver Disease: Clearing the Path to the First Approved Drug

MASH — metabolic dysfunction-associated steatohepatitis, the progressive form of fatty liver disease — has long lacked effective pharmacological treatment. GLP-1 medications have emerged as the most promising class for this indication.

Multiple trials have shown that semaglutide and tirzepatide produce significant reductions in hepatic fat and improvements in liver histology in people with MASH. This is partly through weight loss and partly through direct hepatic GLP-1 receptor effects that reduce hepatic inflammation and fat accumulation independently of systemic metabolic changes. For more on this specific application, see our deep-dive on GLP-1 drugs and liver health.

Resmetirom — the first specifically approved MASH drug — was approved by the FDA in March 2024. GLP-1 medications are not yet specifically approved for MASH in the UK, but they represent the most likely next class of approved treatments based on current trial data.

Addiction: The Most Surprising Signal

Perhaps the most unexpected and most widely discussed emerging indication for GLP-1 drugs is addiction — and the evidence, while still preliminary, is genuinely intriguing.

A 2026 review of ClinicalTrials.gov registrations identified 33 clinical trials of GLP-1 receptor agonists for substance use disorders — primarily focused on alcohol and nicotine, with some trials for stimulant and opioid use disorders. This represents a dramatic expansion of clinical research interest driven by consistent preclinical and early clinical signals.

The mechanistic basis is biologically coherent. GLP-1 receptors are expressed in the mesolimbic dopaminergic system — the brain's reward circuitry — including the nucleus accumbens, ventral tegmental area, and prefrontal cortex. These regions are central to addiction, compulsive behaviour, and reward processing. When GLP-1 receptors in these areas are activated, they modulate dopamine release and attenuate reward-driven behaviours, reducing the motivational salience of addictive substances.

In preclinical studies, GLP-1 receptor agonists consistently reduce alcohol intake, cocaine self-administration, and nicotine consumption in animal models. In early human studies, people taking GLP-1 medications for weight loss have reported spontaneous reductions in alcohol cravings, gambling urges, and other compulsive behaviours — anecdotal signals that prompted the wave of clinical trials now underway.

Lorenzo Leggio, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism, has been among the most cited researchers in this space. His team's early-phase trial data, presented at the 2025 Research Society on Alcoholism annual meeting, suggested that participants receiving semaglutide reported reduced urges to drink compared to placebo groups — though researchers cautioned that sample sizes were small and results preliminary.

As of April 2026, no GLP-1 drug is approved for addiction disorders. The evidence is at the stage of promising signals warranting larger trials — not clinical validation. But 33 registered trials represents genuine scientific momentum, and the mechanistic case is stronger than for many drugs that have progressed to approval.

A systematic review covering preclinical and clinical investigations up to January 2025 concluded that GLP-1RAs modulate mesolimbic dopaminergic signalling and attenuate reward-driven behaviours, positioning them as promising candidates for novel interventions in addiction medicine — while acknowledging that the evidence base for clinical application is still developing.

Alzheimer's Disease: A Mixed Picture

The Alzheimer's story is more complex — and more honest about the limits of the evidence.

GLP-1 receptors are expressed in brain regions affected by Alzheimer's disease, and the anti-inflammatory, neuroprotective, and metabolic mechanisms of GLP-1 drugs provide a biologically plausible basis for potential benefit. The epidemiological signal from electronic health record studies suggested that people taking GLP-1 medications had lower rates of dementia — though these findings are highly susceptible to confounding, as GLP-1 users tend to be wealthier, have better healthcare access, and have more proactive health management than non-users.

The clinical trial evidence is less encouraging. Semaglutide has now failed two major Alzheimer's trials — showing no significant slowing of cognitive decline compared to placebo. Sarah Ackley, a dementia epidemiologist at Brown University, was not surprised by the failure and noted that the observational advantages of GLP-1 users likely reflect their better baseline health rather than drug-specific cognitive protection.

Researchers remain cautiously optimistic about subgroups and different formulations — the hypothesis that GLP-1 drugs may be more effective at earlier disease stages, in metabolically compromised populations, or in combination with other agents has not yet been adequately tested. But the current evidence does not support GLP-1 drugs as a dementia treatment or prevention strategy.

GLP-1 RAs demonstrate promising efficacy in Alzheimer's and Parkinson's based on preclinical and early clinical data — but it is important to emphasise that promising efficacy in early studies and failure in Phase 3 trials are features of almost every drug class that has been tested in Alzheimer's disease. The evidence, for now, sits in the "some evidence" category — real enough to continue investigating, not strong enough to act on clinically.

Concussion and Traumatic Brain Injury: Early and Intriguing

The concussion application is the most speculative but also, in some ways, the most mechanistically compelling of the emerging GLP-1 indications.

A narrative review published in 2024 — one of the first systematic examinations of GLP-1 drugs in traumatic brain injury — identified consistent neuroprotective effects in cell and mouse models of mild traumatic brain injury. The proposed mechanism: GLP-1 receptors in the brain modulate neuroinflammation, which is the primary driver of secondary injury following concussion. By attenuating the cytokine cascade and blood-brain barrier disruption that follows traumatic brain injury, GLP-1 drugs may reduce the neurological sequelae that cause persistent post-concussion symptoms.

The concussion application gained public attention through a New York Times guest essay describing a woman with severe post-concussion syndrome lasting ten years after a cycling accident who experienced significant improvement after starting a GLP-1 medication. These anecdotal reports are consistent with the preclinical mechanism but cannot be used as clinical evidence.

As of April 2026, there are no human clinical trials specifically examining GLP-1 drugs for post-concussion syndrome or TBI recovery. The evidence is at the stage of cell and animal models with biologically plausible mechanisms and anecdotal human reports — not anywhere near clinical application. The evidence is mixed regarding the neurological effects of GLP-1s, with traumatic brain injury not yet included in systematic evidence reviews.

This is worth watching — but worth watching with appropriate scientific caution.

Cancer: A 17% Risk Reduction Across 14 Cancers

A 2025 study by University of Florida researchers found that GLP-1 medications are associated with a 17% lower risk of developing 14 obesity-associated cancers, including endometrial, meningioma, and ovarian cancers.

The mechanism, as described by obesity specialist Dr Sonya Daryanani of Nova Southeastern University, relates to the reduction in chronic inflammation that GLP-1 drugs produce: decreasing the chronic inflammatory effect can really help in reducing tumours, with the mechanism of each cancer being somewhat different.

This is observational data and is subject to confounding — as with the Alzheimer's associations, GLP-1 users have systematically better health outcomes in electronic health record studies for reasons that are not all pharmacological. But a 17% risk reduction across 14 cancer types, if even partially causal, represents a meaningful population-level benefit. The ongoing expansion of GLP-1 prescribing at population scale will generate more definitive evidence over the next decade.

The Side Effects Requiring Honest Coverage

An article covering the expanding benefits of GLP-1 drugs would be incomplete without addressing the side effects that are being documented alongside them.

Gastrointestinal effects — nausea, vomiting, diarrhoea, and constipation — are the most common and are dose-dependent. Most resolve within weeks of dose stabilisation.

Muscle loss — rapid weight loss with inadequate protein intake and no resistance exercise produces lean tissue loss alongside fat loss. This is not unique to GLP-1 medications but is more pronounced at the higher weight loss magnitudes they achieve. Protein intake and resistance training during treatment are important protective measures.

Hair loss — documented in clinical trials as directly proportional to the rate and total amount of weight loss rather than the medication itself. Telogen effluvium from rapid weight loss is the mechanism.

Mood flattening and apathy — an emerging and under-discussed concern. Several studies are underway to better understand why some people lose motivation for activities and experience apathy while on GLP-1 medications. The dopaminergic modulation that may reduce addictive cravings may also blunt reward responses more broadly in some individuals. This is a genuine signal warranting serious investigation.

Rebound weight gain — most people regain significant weight within twelve months of stopping GLP-1 medications without sustained lifestyle changes. This is the most practically significant limitation of the medications as currently used.

Frequently Asked Questions

What conditions are GLP-1 drugs now approved for beyond diabetes?

As of April 2026, GLP-1 medications have regulatory approval in various jurisdictions for: type 2 diabetes, weight management in obesity, cardiovascular risk reduction in overweight/obese adults with established CVD, chronic kidney disease in patients with type 2 diabetes, and obstructive sleep apnoea. These represent the established, evidence-based indications. Multiple further indications are in clinical trials but not yet approved.

Do GLP-1 drugs actually help with addiction?

The preclinical evidence is consistent and mechanistically coherent — GLP-1 receptors in the brain's reward system modulate dopamine and reduce reward-driven behaviour in animal models. Early human data is promising but from small, preliminary trials. As of April 2026, no GLP-1 drug is approved for addiction disorders. Thirty-three clinical trials are currently registered, primarily for alcohol and nicotine use disorders. Results from larger trials are expected over the next two to three years.

Did Ozempic fail in Alzheimer's trials?

Yes — semaglutide failed to show significant slowing of cognitive decline in two major Alzheimer's trials. The observational data suggesting lower dementia rates in GLP-1 users likely reflects the better overall health profile of this population rather than drug-specific cognitive protection. Some researchers remain cautiously optimistic about earlier disease stages or different patient subgroups, but the current evidence does not support GLP-1 drugs as an Alzheimer's treatment or prevention strategy.

Can GLP-1 drugs help with concussion recovery?

The evidence is very early — cell and animal models show neuroprotective effects through neuroinflammation reduction, and there are anecdotal human reports of improved post-concussion symptoms. As of April 2026, no human clinical trials have specifically examined GLP-1 drugs for post-concussion syndrome. This is a mechanistically interesting area at a pre-clinical stage.

Are GLP-1 drugs associated with reduced cancer risk?

A 2025 University of Florida study found GLP-1 medications associated with a 17% lower risk across 14 obesity-associated cancers. This is observational data subject to confounding. The proposed mechanism involves reduction of chronic inflammation that drives tumour development. The finding is interesting and warrants further investigation but does not establish GLP-1 drugs as cancer-preventive agents.

What are the most concerning side effects of GLP-1 drugs?

Beyond the well-documented gastrointestinal effects, the most clinically significant concerns are: muscle loss during rapid weight loss (mitigated by adequate protein and resistance exercise), mood flattening and apathy in some users, and near-universal weight regain upon stopping without sustained lifestyle changes. These should be part of any honest conversation about starting these medications.

The Bottom Line

GLP-1 receptor agonists began as diabetes drugs, became the most discussed weight loss medications of the decade, and are now revealing themselves as something considerably broader — a class of drugs that act on fundamental cellular mechanisms including inflammation, mitochondrial function, and reward processing across multiple organ systems.

The cardiovascular and renal benefits are now robustly established and approved. The sleep apnoea indication is approved. The liver disease application is advancing toward approval. The addiction signal is compelling enough to have generated 33 clinical trials. The Alzheimer's application has failed in its first major tests but remains under investigation. The concussion angle is speculative but mechanistically interesting.

What the evidence does not yet support is treating these medications as universally beneficial or side-effect-free. The risks — muscle loss, mood flattening, weight regain on cessation — are real. The expanded benefit profile makes GLP-1 medications among the most consequential drug class of the past decade. But they are tools with specific indications, not a universal solution.

For the metabolic and lifestyle foundations that these medications work best alongside, the Gut Reset, Liver Reset and Junk Food Reset from the Reset Series™ address the dietary and lifestyle context in which GLP-1 treatment produces its best outcomes — and pair naturally with the Reset Companion for tailored daily support.

Related reading: Weight Loss Injections UK 2026: Mounjaro vs Wegovy vs Ozempic Compared · BMI, Weight-Loss Injections and Who They're Actually For · GLP-1 Drugs and Liver Health: What the Research Shows.

Popular Articles